Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Other Non-Current Liabilities of $681000.0 for Q1 2026, down 90.54% year-over-year from $7.2 million in Q1 2025, and down 77.15% quarter-over-quarter from $3.0 million in Q4 2025.
Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Other Non-Current Liabilities for 14 consecutive years, with $681000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 90.54% year-over-year to $681000.0; the TTM figure through Mar 2026 stood at $681000.0 (down 90.54% YoY), while the FY2025 annual figure was $3.0 million, down 42.43% from the prior year.
- Other Non-Current Liabilities fell to $681000.0 in Q1 2026 per AKBA's latest filing, from $3.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $83.1 million in Q1 2022 and bottomed at $681000.0 in Q1 2026.
- Historically, Other Non-Current Liabilities has averaged $18.6 million across 5 years, with a median of $5.0 million in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 3225.64% in 2022 and fell as far as 99.1% in 2022.
- Akebia Therapeutics' Other Non-Current Liabilities stood at $760000.0 in 2022, then changed by 0.0% to $760000.0 in 2023, then soared by 581.05% to $5.2 million in 2024, then slumped by 42.43% to $3.0 million in 2025, then sank by 77.15% to $681000.0 in 2026.
- Business Quant data shows AKBA's Other Non-Current Liabilities at $681000.0 in Q1 2026, $3.0 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | 681,000.00 |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.36 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | 2.64 Mn |
| Mar 31, 2024 | 4.98 Mn |
| Sep 30, 2023 | 760,000.00 |
| Jun 30, 2023 | 760,000.00 |
| Mar 31, 2023 | 16.77 Mn |
| Dec 31, 2022 | 760,000.00 |
| Sep 30, 2022 | 83.10 Mn |
| Jun 30, 2022 | 74.61 Mn |
| Mar 31, 2022 | 83.14 Mn |
| Dec 31, 2021 | 84.21 Mn |
| Sep 30, 2021 | 77.39 Mn |
| Jun 30, 2021 | 85.36 Mn |